CliffBio
small molecule

ARNUITY ELLIPTA

FLUTICASONE FUROATE

Loss of exclusivityMarch 2026FDA regulatory exclusivity expiry
CompanyGLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Drug detail

Brand nameARNUITY ELLIPTA
Active ingredientFLUTICASONE FUROATE
Strength0.05MG/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalMay 2018
Marketing statusRX

Regulatory exclusivity

CodeExpires
M-290March 2026

More from GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

ARNUITY ELLIPTA patent cliff — loss of exclusivity March 2026 | CliffBio